Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: "Bounciest Democrat on November's statewide ballot? It might be Hank Gilbert, making his second hard charge for state agriculture commissioner versus Todd Staples, the Republican who topped him four years ago. Gilbert, ever prowling for issues, recently trumpeted that the Texas Department of Agriculture is looking at buying thousands of stress balls -- squeezable toys. He said in a Sept. 24 press release: ""Make no mistake, Texans love their balls: footballs, baseballs, basketballs, and soccer balls. But 300,000 stress balls? It seems a little extreme, but that's the quantity of grape, barbell, and book-shaped polyurethane stress balls the Texas Department of Agriculture could be spending taxpayer dollars on..."" Really? To our inquiry, Gilbert's campaign provided Web links to the agriculture agency's June request for bids as well as a September post on a state website indicating that a $99,000 contract to provide promotional materials was awarded to a Massachusetts company, Oceans Promotions. We downloaded the June 29 bid-request package from a site for state requisitions overseen by the state comptroller's office. The package shows the department was seeking bids to provide up to 300,000 stress ""relievers,"" which we're guessing are not balls because they're not round. Precisely, the package says, the agency sought bids to make ""promotional items with logo imprints to follow through on (the) TDA Food and Nutrition Texans Bring It Campaign,"" with the items to include grape-shaped stress relievers with ""Texans Bring It"" written on them or ""Eating Right,"" which would be made of polyurethane and be two inches high by three inches wide. The package says a second set of stress relievers, each one called ""Dumbbell,"" would be imprinted ""Texans Bring It"" and ""Exercise"" and be five inches high by 1.8 inches in diameter. A third stress reliever would be imprinted ""Book"" and ""Texans Bring It,"" according to the bid package, while other promotional items would include pencils, buttons and bumperstickers. The package says the bids were sought for various quantities, starting from 2,500 and topping out at 100,000 each. It electronically links to a Branders.com site showing what the agency wanted the stress relievers to look like (our interpretation: bunches of purple grapes). Is all this a real deal? To our inquiry, Bryan Black, Staples' spokesman, replied via e-mail: ""An invitation for bid was issued for these federally funded educational items to reduce the $5.8 billion avoidable health care expenditures, paid by taxpayers, associated with overweight and obesity health problems."" We followed up with Black, asking if it's accurate to conclude that up to 300,000 of the stress relievers are being purchased. We also wondered why the purchase was being made. Black said he'd limit his comment to his e-mailed statement. Surely the agency would pipe up if Gilbert got its purchase plans wrong." Claim: Hank Gilbert Says the Texas Department of Agriculture seeks to purchase up to 300,000 promotional stress balls.
Example Output: Hank Gilbert says Texas Department of Agriculture could be buying up to 300,000 stress balls

Example Input: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company's most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. "We are delighted with the final data," Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration "to determine next steps" for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a "breakthrough" drug by the FDA last April based on initial data from the trial. The FDA grants "breakthrough" status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
Example Output: Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

Example Input: Paragraph: WHY WEAR A MASK? Health experts say face coverings help prevent the spread of COVID-19. Cloth coverings cannot block the virus itself. However, they can provide some protection from droplets from breath and saliva that can carry the disease. Some people don't realize they are infected because they have no symptoms. If they wear a mask, it limits the possibility of them unwittingly spreading the disease. HOW IS THE LOS ANGELES MASK REQUIREMENT DIFFERENT? The city of Los Angeles has the strictest requirement of any major city in the state. Mayor Eric Garcetti issued an order this week saying: "All individuals engaging in outdoor activities, except for water activities, must wear a cloth face covering." That includes everything from walking around the block to skateboarding. The order exempts children under 2 and people with certain disabilities. Even in surrounding Los Angeles County it's a little less stringent. Health Director Dr. Barbara Ferrer say masks aren't needed for solitary walks or jogs. DO I HAVE TO WEAR IT IN THE CAR? Garcetti says no. But he emphasized wearing it other places when away from home and applying social distancing are foundational elements to continuing the progress Los Angeles has made against the virus. ABOUT THE VIRUS As of Friday, 1,755 people have died due to COVID-19 in Los Angeles County, which has a quarter of the state's nearly 40 million residents but more than half the deaths. Slight decreases in hospitalizations have occurred over the last week and a half and "we are encouraged," Ferrer said. For the most people, the virus causes mild or moderate symptoms for up to three weeks. The vast majority recover. Some older adults and people with existing health problems can experience severe illness including pneumonia and death. Claim: Things to Know: Face covering rules vary by jurisdiction.
Example Output:
Health authorities want people to wear masks or face coverings outdoors to help prevent spread of the coronavirus, but is it a hard and fast rule? It depends. Here are things to know: